<HashMap><database>biostudies-literature</database><scores/><additional><omics_type>Unknown</omics_type><volume>49(1)</volume><submitter>Garrick A</submitter><funding>Colorado State University</funding><pubmed_abstract>The purpose of this study was to evaluate the pharmacokinetics of oral (PO) ondansetron compared to intravenous (IV) ondansetron in eight healthy client-owned dogs. Dogs were randomized to one of two protocols in a crossover design, receiving PO or IV ondansetron at a dose of 1 mg/kg on Day 0 and the opposite formulation at an equal dose on Day 7. Plasma was collected at baseline and 1, 2, 4, and 8 h post administration. Ondansetron concentrations were measured utilizing liquid chromatography/mass spectrometry. For IV administration, AUC&lt;sub>0-8h&lt;/sub> was 1181 ± 619 ng/mL*h, with all dogs having detectable plasma concentrations at all time points. For PO administration, mean C&lt;sub>max&lt;/sub> was 22 ± 11.3 ng/mL and AUC&lt;sub>0-8h&lt;/sub> was 61.7 ± 45.4 ng/mL*h, with all dogs having undetectab</pubmed_abstract><journal>Journal of veterinary pharmacology and therapeutics</journal><pagination>17-21</pagination><full_dataset_link>https://www.ebi.ac.uk/biostudies/studies/S-EPMC12796776</full_dataset_link><repository>biostudies-literature</repository><pubmed_title>Bioavailability of Oral Ondansetron in Dogs: A Crossover Study.</pubmed_title><pmcid>PMC12796776</pmcid><pubmed_authors>Diaz A</pubmed_authors><pubmed_authors>Gustafson D</pubmed_authors><pubmed_authors>Garrick A</pubmed_authors><pubmed_authors>Quimby J</pubmed_authors><pubmed_authors>Shropshire S</pubmed_authors><pubmed_authors>Zersen K</pubmed_authors></additional><is_claimable>false</is_claimable><name>Bioavailability of Oral Ondansetron in Dogs: A Crossover Study.</name><description>The purpose of this study was to evaluate the pharmacokinetics of oral (PO) ondansetron compared to intravenous (IV) ondansetron in eight healthy client-owned dogs. Dogs were randomized to one of two protocols in a crossover design, receiving PO or IV ondansetron at a dose of 1 mg/kg on Day 0 and the opposite formulation at an equal dose on Day 7. Plasma was collected at baseline and 1, 2, 4, and 8 h post administration. Ondansetron concentrations were measured utilizing liquid chromatography/mass spectrometry. For IV administration, AUC&lt;sub>0-8h&lt;/sub> was 1181 ± 619 ng/mL*h, with all dogs having detectable plasma concentrations at all time points. For PO administration, mean C&lt;sub>max&lt;/sub> was 22 ± 11.3 ng/mL and AUC&lt;sub>0-8h&lt;/sub> was 61.7 ± 45.4 ng/mL*h, with all dogs having undetectab</description><dates><release>2026-01-01T00:00:00Z</release><publication>2026 Jan</publication><modification>2026-06-06T15:27:18.743Z</modification><creation>2026-06-01T03:10:46.273Z</creation></dates><accession>S-EPMC12796776</accession><cross_references><pubmed>40924364</pubmed><doi>10.1111/jvp.70024</doi></cross_references></HashMap>